Drug Target Review

FEBRUARY 1, 2024

This can present challenges when attempting to recruit an enriched patient population for clinical trials. Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? The lack of heterogeneity can introduce significant risk into mid- to late-stage studies.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

PPD

MAY 18, 2023

Yet, four out of five care partners of people with neurodegenerative disorders have never been informed of clinical trial opportunities , according to a survey of more than 250 caregivers conducted by PPD, the clinical research business of Thermo Fisher Scientific. There’s little time to lose.

Clinical Trials 86

Clinical Trials Trials Clinical Research Doctors 86

Broad Institute

NOVEMBER 25, 2024

As a proof of concept, a drug designed to target a newly discovered biological node is showing efficacy in treating rare genetic diseases in the kidney, the eye, and the brain and is now making its way to clinical trials in collaboration with a pharmaceutical partner. You can learn more about how clinical trials work here.

Clinical Trials 52

Clinical Trials Disease Trials Therapies 52

Drug Target Review

DECEMBER 16, 2024

This field allowed me the privilege of tending to children in the hospital and building long-term relationships with them and their families. In addition to this, I also chaired national trials evaluating an anti-GD2 antibody in pediatric osteosarcoma.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

KIF1A

APRIL 25, 2024

She is scheduled to be the 2nd patient in the world to receive ASO therapy for KAND. March 2023 – We met with n-Lorem and found out Susannah’s ASO (1st KAND patient to receive ASO therapy for KAND) would work for Sloane. Sloane is an adorable 3 year old with KAND. Hello KIF1A Community! We are also paying for our housing.

Therapies 52

Therapies FDA Approval FDA Treatment 52

The Pharma Data

DECEMBER 28, 2020

LY-CoV555 Not Efficacious for Hospitalized Patients With COVID-19. 28, 2020 — The neutralizing monoclonal antibody LY-CoV555, given in conjunction with remdesivir, is not efficacious for hospitalized patients with COVID-19 without end-organ failure, according to a study published online Dec. Professional. MONDAY, Dec.

Hospitals 52

Hospitals Science Therapies Trials 52

Broad Institute

AUGUST 19, 2024

Jude Children’s Research Hospital have discovered that oleic acid, one of the most abundant fatty acids in the body, restores a healthy balance of vaginal microbes in a laboratory model of BV. At the Ragon Institute, Kwon’s lab is working to move this research toward a human clinical trial. “We Paper cited Zhu M et al.

Hospitals 121

Hospitals Treatment Medical Schools Science 121

The Pharma Data

NOVEMBER 30, 2020

The UK-based RECOVERY trial, which is evaluating multiple treatments for COVID-19, will add the inexpensive anti-inflammatory drug colchicine to the list of therapies being tested in hospitalized patients. They said it is likely to be several months before colchicine’s efficacy is known. Source link.

Treatment 52

Treatment Trials Hospitals Therapies 52

Drug Target Review

JANUARY 12, 2024

This one size fits all approach to drug prescribing still pervades in mostly all therapy areas except oncology. Therefore, having biomarker information is useful for separating individuals and ensuring that you treat an individual as an individual and can tailor their therapy. Most drugs do not work in all people.

Doctors 111

Doctors Clinical Trials Treatment Therapies 111

SCIENMAG: Medicine & Health

JUNE 14, 2023

Three young patients with relapsed T-cell leukaemia have now been treated with base-edited T-cells, as part of a ‘bench-to-bedside’ collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

Therapies 58

Therapies Clinical Trials Hospitals Trials 58

Olympian Clinical Research

OCTOBER 14, 2021

If you’re thinking about joining a clinical trial, there are many benefits you could look forward to. But how can you tell if clinical trials are right for you? We’ve outlined five reasons why joining a clinical trial might be in your best interest. You’re Helping to Advance Medical Knowledge.

Clinical Trials 52

Clinical Trials Trials Doctors Therapies 52

Advarra

MARCH 6, 2025

For more than 35 years, Advarra has been committed to protecting the rights and welfare of clinical trial participants while helping to improve healthcare outcomes, advancing medical knowledge, and bringing innovative, life-extending treatments to market that benefit millions of patients worldwide.

Clinical Research 52

Clinical Research Research Clinical Trials Bioethics 52

The Pharma Data

JANUARY 17, 2021

The Phase IIa POC studies will be conducted after a Phase Ib dose escalation study evaluating the tolerability and activity of proenzyme therapy in patients with advanced solid tumors is completed, planned for 2021, at the Peter Mac Cancer Center, Melbourne, Australia. About Propanc Biopharma, Inc. Propanc Biopharma, Inc.

Therapies 52

Therapies Clinical Trials Trials Hospitals 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 3, 2020

The approval was based on data from the Phase 3 APeX-2 trial, which showed that ORLADEYO could significantly reduce attacks at the 24-week mark. Subjects who completed 48 weeks of treatment in the Phase 3 trial saw reductions in their HAE attack rates, from an average of 2.9 The reduction was sustained through 48 weeks in the study.

FDA Approval 52

FDA Approval Therapies FDA Trials 52

Advarra

FEBRUARY 4, 2025

At a busy research site, a clinical trial is ready to launch but its stuck in limbo over a single paragraph in the informed consent form (ICF). While the trial waits for approval, patients who are eager for a new treatment face delay. Language relating to the potential cost of participation. Age isnt the only factor to consider.

Clinical Trials 52

Clinical Trials Trials Compliance Therapies 52

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

APRIL 19, 2022

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies. — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Treatment Hospitals 52

Broad Institute

NOVEMBER 7, 2023

While RA therapies targeted to specific inflammatory pathways have emerged, only some patients’ symptoms improve with treatment, emphasizing the need for multiple treatment approaches tailored to different disease subtypes. Adapted from a press release issued by Brigham and Women's Hospital.

Treatment 96

Treatment RNA Hospitals Disease 96

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Disease 52

Disease Trials Treatment Clinical Trials 52

Cytel

FEBRUARY 20, 2024

Negative binomial probability distribution can be used to model the number of times a particular outcome occurs during a clinical trial. Here, I explain this statistical methodology and its application in adaptive group sequential clinical trial designs.

Clinical Trials 59

Clinical Trials Hospitals Trials Therapies 59

The Pharma Data

JANUARY 9, 2021

(NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.

Therapies 52

Therapies Trials Clinical Trials Treatment 52

Broad Institute

OCTOBER 4, 2023

A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy. AbbVie and Calico are currently testing the molecule and another related molecule , also developed by AbbVie and Calico, in phase 1 clinical trials. We were really impressed by that.”

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

DECEMBER 21, 2020

The trial will be conducted at 10 sites across Germany and led by principal investigator Prof. The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We Mascha Binder, M.D.,

Vaccine 52

Vaccine Trials Clinical Trials Clinical Development 52

The Pharma Data

APRIL 27, 2023

The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints 1. The APPOINT-PNH trial also showed clinically meaningful benefits for secondary endpoints 1. These data were presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

Trials 40

Trials Treatment Hospitals Therapies 40

The Pharma Data

NOVEMBER 15, 2020

16, 2020 /PRNewswire/ –: iSTAR Medical , a medtech company developing minimally invasive ophthalmic implants for treatment of patients with glaucoma, today announced positive one-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject TM. WAVRE, Belgium , Nov.

Trials 52

Trials Clinical Trials Treatment Engineering 52

The Pharma Data

JANUARY 12, 2021

a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

The Pharma Data

JANUARY 10, 2021

SH ) submitted its pivotal phase III clinical trial application (IND) of national class I innovative drug Chiauranib to NMPA, for the treatment of Small Cell Lung Cancer (SCLC) as a single agent for the patients after 2nd-line systemic chemotherapy and recurrence afterwards. SHENZHEN, China , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Drug Target Review

MAY 18, 2023

Tedesco Distinguished Chair of Paediatric Haematology and Oncology, are collaborating as co-principal investigators on a new clinical trial, which has been awarded a $2.3 The trial represents an early-stage effort to determine the viability of this approach. Kutlar says the possibilities of this additional therapy are exciting.

Disease 80

Disease Clinical Trials Drugs Trials 80

The Pharma Data

SEPTEMBER 30, 2020

The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation (OIC) in adults who have already received laxative treatment, meaning the therapy can now be used in routine use on the NHS in England and Wales.

Hospitals 52

Hospitals Therapies Treatment Trials 52

The Pharma Data

DECEMBER 21, 2020

The Phase III study was conducted as an open-label trial with patients receiving either an Orgovyx pill daily or injections of Abbvie’s Lupron as an injection every three months. In the trial, Myovant’s drug outperformed Abbvie’s by suppressing testosterone to castration levels in 96.7%, compared to their competitor’s 88.8%. . “We

FDA Approval 52

FDA Approval FDA Therapies Drugs 52

The Pharma Data

JANUARY 5, 2021

5, 2021 — Stem cells derived from a baby’s umbilical cord can help save the lives of the sickest COVID-19 patients, results from a small new clinical trial suggest. The therapy also proved safe, with no infusion-related serious adverse events. TUESDAY, Jan. The stem cells also sped recovery time.

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

APRIL 22, 2023

Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs.

Therapies 40

Therapies Engineering Clinical Trials Hospitals 40

biobide

FEBRUARY 2, 2024

Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies. This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

The Pharma Data

AUGUST 16, 2021

Novartis today announced positive results from two Phase III clinical trials assessing Beovu ® (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Both trials demonstrated an overall well-tolerated safety profile. for Beovu vs. 1.7% for Beovu vs. 1.7%

Trials 52

Trials Clinical Trials Treatment Disease 52

The Pharma Data

JULY 8, 2021

The update includes an addition to the Indications and Usage section of the label (Section 1) to emphasize the disease stages studied in the clinical trials, as seen below ( italics to note updated language). Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52